Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. Al-Batran SE, et al. Among authors: zander t. BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9. BMC Cancer. 2017. PMID: 29282088 Free PMC article. Clinical Trial.
CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H, Al-Batran SE, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze TO. Schmalenberg H, et al. Among authors: zander t. J Cancer Res Clin Oncol. 2018 Mar;144(3):559-569. doi: 10.1007/s00432-017-2565-5. Epub 2017 Dec 28. J Cancer Res Clin Oncol. 2018. PMID: 29285668 Clinical Trial.
High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas.
Loeser H, Schallenberg S, von Winterfeld M, Tharun L, Alakus H, Hölscher A, Bollschweiler E, Buettner R, Zander T, Quaas A. Loeser H, et al. Among authors: zander t. Oncotarget. 2017 Dec 11;8(70):115179-115189. doi: 10.18632/oncotarget.23112. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383151 Free PMC article.
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S. Quaas A, et al. Among authors: zander t. BMC Gastroenterol. 2018 May 31;18(1):75. doi: 10.1186/s12876-018-0803-1. BMC Gastroenterol. 2018. PMID: 29855275 Free PMC article.
Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS, Ulase D, Bollschweiler E, Chon SH, Berlth F, Zander T, Alakus H, Hölscher AH, Bruns CJ, Schallenberg S, Quaas A, Loeser H. Plum PS, et al. Among authors: zander t. J Cancer Res Clin Oncol. 2018 Sep;144(9):1731-1739. doi: 10.1007/s00432-018-2698-1. Epub 2018 Jul 4. J Cancer Res Clin Oncol. 2018. PMID: 29974234
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H. Pasternack H, et al. Among authors: zander t. Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4. Sci Rep. 2018. PMID: 30297788 Free PMC article.
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S. Quaas A, et al. Among authors: zander t. BMC Gastroenterol. 2019 Feb 4;19(1):21. doi: 10.1186/s12876-019-0942-z. BMC Gastroenterol. 2019. PMID: 30717682 Free PMC article.
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.
Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Persa OD, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A. Loeser H, et al. Among authors: zander t. Oncoimmunology. 2019 Feb 27;8(5):e1581546. doi: 10.1080/2162402X.2019.1581546. eCollection 2019. Oncoimmunology. 2019. PMID: 31069143 Free PMC article.
371 results